MedTrace Logo

Xolair Enhances Oral Desensitization in Peanut Allergic Patients

NCT01290913 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2015-04-07

Study results available
· View outcomes & findings →

Summary

This is a pilot feasibility study, using Xolair pretreatment for oral peanut desensitization.

Conditions

Interventions

DRUG

Omalizumab

Omalizumab is an antibody that helps decrease allergic responses in the body

Sponsors & Collaborators

  • Lynda Schneider

    lead OTHER

Principal Investigators

  • Rima T Rachid, MD · Children's Hospital, Harvard Medical School

  • Lynda Schneider, MD · Children's Hospital, Harvard Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01290913 on ClinicalTrials.gov